

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LEPU BIOPHARMA CO., LTD.  
樂普生物科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2157)**

**ANNOUNCEMENT  
DELAY IN DESPATCH OF CIRCULAR  
AND  
CANCELLATION OF BOOK CLOSURE PERIOD**

Reference is made to the announcement of Lepu Biopharma Co., Ltd. (the “**Company**”) dated Monday, November 13, 2023 (the “**Announcement**”) in relation to, among other things, the CDMO Services Framework Agreement that the Company conditionally entered into on even date, and to the announcement of the Company dated Monday, December 4, 2023 (the “**Book Closure Announcement**”) in relation to the closure of register of members for the 2023 second extraordinary general meeting (the “**EGM**”) originally scheduled to be held on Friday, December 22, 2023 for the purpose of considering and, if thought fit, approving the CDMO Services Framework Agreement (including the Proposed Caps) and the transactions contemplated thereunder. Unless otherwise defined, capitalized terms used in this announcement shall have the same meaning as those defined in the Announcement.

**DELAY IN DESPATCH OF CIRCULAR**

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) a letter from the Board; (ii) a letter of recommendation from the Independent Board Committee; (iii) a letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders; (iv) further details on the continuing connected transactions (including the Proposed Caps); and (v) a notice to convene the EGM was expected to be despatched to the Shareholders on or before Monday, December 4, 2023.

As additional time is required to finalize certain transaction terms of the CDMO Services Framework Agreement and to finalize relevant information for inclusion in the Circular, the despatch date of the Circular and the notice of the EGM is expected to be postponed to a date falling on or before Friday, January 19, 2024.

## **CANCELLATION OF BOOK CLOSURE PERIOD**

As a result of the delay in the despatch of the Circular and the postponement of the date of the EGM, the book closure period as stated in the Book Closure Announcement will be cancelled and the register of members of the Company will no longer be closed from Tuesday, December 19, 2023 to Friday, December 22, 2023 (both days inclusive).

The Company will make further announcement(s) in due course when the new book closure period and the date of the corresponding EGM is determined, and will despatch the Circular, notice and related form of proxy regarding the EGM to the Shareholders as soon as practicable.

On behalf of the Board  
**Lepu Biopharma Co., Ltd.**  
**Dr. Pu Zhongjie**  
*Chairman of the Board and Executive Director*

Shanghai, the PRC  
December 8, 2023

*As at the date of this announcement, the board of directors of the Company comprises Dr. Pu Zhongjie (chairman), Dr. Sui Ziyue (chief executive officer) and Dr. Hu Chaohong (co-chief executive officer) as executive directors, Ms. Pu Jue, Mr. Yang Hongbing and Mr. Lin Xianghong as non-executive directors, and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive directors.*